A. Disease activity and location at presentation

Disease activity

CD^{c} (PCDAI^{d})

Group A: mean ± SD^{e}

38.75 ± 2.7

45 ± 3.3

31.3 ± 3.44

Group B:mean ± SD

30.76 ± 2.02

32.2 ± 2.26

29.6 ± 3.5

P

0.05

0.003

0.7

UC^{f} (PUCAI^{g})

Group A: mean ± SD

47.2 ± 2.5

55.2 ± 2.2

41.2 ± 2.7

Group B: mean ± SD

41.4 ± 1.8

41.6 ± 2.5

39.8 ± 3.65

P

0.03

0.03

0.8

OR^{h}

1.09

1.11

1.03

95 % CI^{i}

1.02–1.1

1.03–1.2

1.01–1.08

Disease location

CD

P

0.3 for L1

0.6 for L1

0.3 for L1

0.05
for L2

0.04
for L2

0.7 for L2

0.4 for L3

0.5 for L3

0.7 for L3

UC

P

0.7 for E1–E2

0.8 for E1–E2

0.6 for E1–E2

0.8 for E3–E4

0.9 for E3–E4

0.9 for E3–E4

B. Biochemical parameters at disease presentation

WBC^{j} (x10^3/mm3)

Group A: mean ± SD

10.1 ± 0.45

10.9 ± 0.7

9.4 ± 0.6

Group B: mean ± SD

8.81 ± 0.35

9.09 ± 0.5

8.5 ± 0.47

P

0.03

0.04

0.3

HCT^{k} (%)

Group A: mean ± SD

33.7 ± 0.57

32.6 ± 0.6

34.8 ± 0.9

Group B: mean ± SD

35.8 ± 0.5

34.9 ± 0.7

36.7 ± 0.6

P

0.005

0.02

0.09

Platelet count (x10^3/mm3)

Group A: mean ± SD

487 ± 18.9

476 ± 21.3

497.5 ± 31.2

Group B: mean ± SD

393 ± 13.4

404 ± 18.6

382 ± 19.3

P

0.002

0.01

0.003

C. Disease course and outcomes

Early treatment with thiopurines (within 3 months of diagnosis)

Group A

58

20

38

Group B

46

17

29

P

0.05

0.7

0.006

OR

1.86

1.04

7.19

95 % CI

1.02–4.33

0.8–2.63

0.9–77.4

Relapses (per patient/per year of followup)

Group A: mean ± SD

1.4 ± 0.2

1.53 ± 1.24

1.03 ± 0.3

Group B: mean ± SD

0.85 ± 0.1

0.9 ± 0.7

0.7 ± 0.13

P

0.05

0.005

0.3

OR

1.2

1.5

1.2

95 % CI

1.01–1.65

0.8–4.45

0.74–2.64

Number of endoscopies (per patient/per year of followup)

Group A: mean ± SD

0.9 ± 0.05

0.9 ± 0.06

0.9 ± 0.09

Group B: mean ± SD

0.75 ± 0.05

0.8 ± 0.07

0.7 ± 0.08

P

0.04

0.2

0.05

OR

1.67

1.2

7.07

95 % CI

1.01–4.19

0.98–1.58

1.09–45.9
